BOSTON, Sept. 30 Solos Endoscopy, Inc.(Pink Sheets: SNDY) is pleased to announce that the Company intends to expandtheir current industry to include and capitalize on the $30 billion minimallyinvasive instrumentation market by implementing a business strategy. TheCompany's strategy is expected to substantially increase its revenue, andsimultaneously increase its customer base.
Solos Endoscopy expects continuous growth in this market becausephysicians are developing new minimally invasive techniques, not only in thetraditional area of general surgery, but also in other medical specialtyareas. This shift in the Company's business strategy will allow many moreprocedures to be performed outside the operating room setting and thisexpansion creates an increased demand for high quality instrumentation in themedical product market.
"Our initiative for 2008 is to enhance the instrumentation that we havedeveloped in the general surgery line, and to move our surgical instrumentdivision into diverse specialties. We believe that we have a great future; ourreputation in the medical industry is that we build excellent instruments andthis, coupled with our new products, will significantly expand our revenue andcustomer base in the future," stated Robert Segersten, President of SolosEndoscopy, Inc.
For additional information on Solos Endoscopy, Inc. please visitwww.solosendoscopy.com .
About Solos Endoscopy, Inc.
Solos Endoscopy, Inc. is a healthcare technology company whose mission isto develop and market breakthrough technology, applications, medical devices,and procedural techniques for the screening, diagnosis, treatment andmanagement of disease and medical conditions. Backed by technical support,Solos' sales team can help make the right buying decisions for the hospital,surgery center, or physician office. Additional information is available onthe Company's website at: www.solosendoscopy.com .
Safe Harbor: This release includes forward-looking statements within themeaning of Section 27A of the Securities Act of 1933 and Section 27E of theSecurities Act of 1934. Statements contained in this release that are nothistorical facts may be deemed to be forward-looking statements. Investors arecautioned that forward-looking statements are inherently uncertain. Actualperformance and results may differ materially from that projected or suggestedherein due to certain risks and uncertainties including, without limitation,ability to obtain financing and regulatory and shareholder approval foranticipated actions.
SOURCE Solos Endoscopy, Inc.